Related Experiment Video
Updated: Jun 27, 2025
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.6K
Identification and verification of a PANoptosis-related long noncoding ribonucleic acid signature for predicting the
Lingling Bao1, Yingquan Ye2, Xuede Zhang3
1Department of Hematology and Oncology, Beilun District People's Hospital, Ningbo, China.
Heliyon
|April 29, 2024
Summary
This study identifies a novel PANoptosis-related long non-coding RNA signature (PRLSig) for lung adenocarcinoma (LUAD). PRLSig aids in predicting patient prognosis and optimizing immunotherapy strategies for LUAD patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Programmed cell death (PCD) pathways, including PANoptosis, are crucial in tumor progression.
- Long non-coding RNAs (lncRNAs) are implicated in cancer malignancy and PCD regulation.
- The role of PANoptosis-associated lncRNAs in lung adenocarcinoma (LUAD) is largely unexplored.
Purpose of the Study:
- To investigate the function of PANoptosis-related lncRNAs in LUAD.
- To develop a prognostic signature based on PANoptosis-associated lncRNAs for LUAD.
- To evaluate the signature's predictive value in the tumor immune microenvironment and its potential for guiding immunotherapy.
Main Methods:
- Development of a PANoptosis-related lncRNA signature (PRLSig) using the least absolute shrinkage and selection operator (LASSO) algorithm.
- Validation of PRLSig stability and accuracy through Kaplan-Meier analysis, Cox regression, receiver operating characteristic (ROC) analysis, and stratification analysis.
- Assessment of PRLSig's association with the immune microenvironment using ESTIMATE, gene set enrichment analysis (GSEA), immune checkpoints, and the cancer immunome database.
Main Results:
- A robust PRLSig was constructed and validated, demonstrating significant predictive power for LUAD patient prognosis.
- PRLSig effectively correlated with key features of the tumor immune microenvironment, including immune cell infiltration and immune checkpoints.
- The signature identified patient subgroups likely to benefit from immunotherapy.
Conclusions:
- The developed PRLSig offers novel insights into the role of PANoptosis-related lncRNAs in LUAD.
- PRLSig can facilitate improved risk stratification for LUAD patients.
- This signature holds potential for optimizing personalized treatment strategies, including immunotherapy, for LUAD.
